Tag archives: Adagene

China's Adagene Inc, a Nasdaq-listed innovative biopharmaceutical company focusing on discovery and development of antibody-based novel cancer immunotherapy, announced collaboration and inked an exclusive license agreement with Sanofi for $2.5 billion on Wednesday, the company said. According to the deal, Adagene will authorize its core technology to Sanofi and help it create new medicines. The potential transaction value to be seen through such cooperation between the domestic biopharmaceutical enterprise with its partner hit a record in its field, said industry insiders. "Original biopharmaceutical developments from China are attracting rising international attention, and new drugs that can truly solve unmet clinical